Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS)

Article Page

Abstract

Background: Upper respiratory tract infections (URTIs) are a major cause of exacerbations in patients with chronic obstructive pulmonary disease (COPD). We assessed the effectiveness of Oscillococcinum® in the protection from URTIs in patients with COPD who had been vaccinated against influenza infection over the 2018–2019 winter season.

Methods: Patients (n=106; mean ± standard deviation age: 66.0 ± 10.3 years; 89.6% men) were randomized into two groups: group V received influenza vaccination only and group OV received influenza vaccination plus Oscillococcinum® (one oral dose per week from inclusion in the study until the end of follow-up, with a maximum of 6 months follow-up over the winter season). The primary endpoint was the incidence rate of URTIs (number of URTIs/1000 patient-treatment exposure days) during follow-up compared between the two groups.

Results: There was no significant difference in any of the demographic characteristics, baseline COPD, or clinical data between the two treatment groups (OV and V). The URTI incidence rate was significantly higher in group V than in group OV (2.9 versus 1.2 episodes/1000 treatment days, difference OV–V = −1.7; p=0.0312). There was a significant delay in occurrence of an URTI episode in the OV group versus the V group (mean ± standard error: 48.7 ± 3.0 versus 67.0 ± 2.8 days, respectively; p=0.0158). Limitations to this study include its small population size and the self-recording by patients of the number and duration of URTIs and exacerbations.

Conclusion: Oscillococcinum may decrease the incidence rate and delay the appearance of URTIs in patients with COPD.

Keywords: chronic obstructive pulmonary disease, chronic respiratory illness, exacerbations, homeopathy, influenza vaccination, Oscillococcinum, upper respiratory tract infection.

Citation: Aouina H, Bamri A, Vesin A, Danno K, Aubry E, Faure C, Boujedaini N. Oscillococcinum® for upper respiratory tract infections and exacerbations in COPD: an observational, prospective study (OXITUNIS). Drugs Context. 2021;10:2021-4-2. https://doi.org/10.7573/dic.2021-4-2

Contributions: HA participated in the conceptualization and investigation of the study, in obtaining resources, and in writing, reviewing and editing the manuscript. AB contributed with funding acquisition and project administration. AV conducted the formal analysis. KD participated in the conceptualization, methodology, and validation of the study and project administration. EA participated in the conceptualization of the study. CF participated in reviewing the manuscript. NB participated in the conceptualization, methodology, validation, and supervision of the study, in writing, reviewing and editing the manuscript, and in funding acquisition. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: HA received honoraria for expert consultancy and investigation from Boiron. AB, KD, EA, CF and NB are employed by Laboratoires Boiron. AV is employed by Delta Consultant and received fees for formal analysis work.

Acknowledgements: Medical writing support was funded by Laboratoires Boiron and provided by NewMed Publishing. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/07/dic.2021-4-2-COI.pdf

Funding declaration: This work was supported by Laboratoires Boiron.

Copyright: Copyright © 2021 Aouina H, Bamri A, Vesin A, Danno K, Aubry E, Faure C, Boujedaini N. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Aouina H, Bamri A, Vesin A, Danno K, Aubry E, Faure C, Boujedaini N. https://doi.org/10.7573/dic.2021-4-2. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/oscillococcinum-for-upper-respiratory-tract-infections-and-exacerbations-in-copd-an-observational-prospective-study-oxitunis

Correspondence: Hichem Aouina, Service de Pneumologie, Hôpital Charles Nicolle, Tunis, Tunisia. Email: hichem.aouina@gmail.com

Provenance: Submitted; externally peer reviewed.

Submitted: 9 April 2021; Accepted: 24 June 2021; Publication date: 29 July 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF